Poised to be the world’s second largest economy, China may develop more Westernized diseases through changes in living conditions, lifestyle, habits, diet, hygiene, and their associated effects on the intestinal microbiome
that may further drive this unprecedented increase of immune-mediated diseases. In summary, the incidence of IBD in Asia remains significantly lower than that in the West. However, we are now seeing a slow but steady increase in IBD incidence that mirrors early increases previously observed in the West. While the etiology and pathogenesis of IBD in Asian populations may be different to that observed in Caucasian populations with regard to both genetic[10-12] and environmental[13, 14] risk factors, these observations may not mitigate a potential looming IBD epidemic in Asia. Now that Zeng et al. have established a study ACP-196 clinical trial population in Guangdong province that can be used to accurately determine IBD incidence, it is essential that these investigators continue to perform incidence studies at intervals to track changes in IBD incidence over time. Such a sentinel site in mainland China will be vital in estimating the effect of IBD incidence changes across much of Asia. “
“The paired box 5 (PAX5) is a member of PAX transcription factors family involved
in the regulation of embryonic development. However, the role of PAX5 in carcinogenesis is largely unclear. We identified that PAX5 is involved in human cancer by methylation-sensitive representational difference analysis. We examined the biological RG 7204 functions and related molecular mechanisms of PAX5 in hepatocellular carcinoma (HCC). Promoter methylation of PAX5
was evaluated by methylation-specific polymerase chain reaction (PCR) and bisulfite genomic sequencing (BGS). The functions of ectopic PAX5 expression were determined by viability assay, colony formation, and cell cycle analyses, along with in vivo tumorigenicity assays. The PAX5 target signal pathway was identified by promoter luciferase assay, chromosome immunoprecipitation (ChIP), and pathway PCR array. PAX5 is expressed in normal human liver tissue, but silenced or down-regulated Sulfite dehydrogenase in 83% (10/12) of HCC cell lines. The mean expression level of PAX5 was significantly lower in primary HCCs as compared to their adjacent normal tissues (P < 0.0001). The promoter methylation contributes to the inactivation of PAX5. Restoring PAX5 expression in silenced HCC cell lines suppressed cell proliferation, induced apoptosis in vitro, and inhibited tumor growth in nude mice (P < 0.0001). The pathway luciferase reporter assay indicated that PAX5 activated p53 and p21 signaling. ChIP analysis demonstrated that PAX5 directly bound to the p53 promoter.